Novorex specializes in developing small-molecule drugs targeting oncology and neurology diseases through fragment-based drug design (FBDD) and artificial intelligence. The company enhances drug efficacy by utilizing biophysical analysis and in vitro/in vivo assays, providing advanced treatment options for patients with complex conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective small-molecule drugs for oncology and neurology is challenging due to the complexity of disease mechanisms and the difficulty in identifying compounds with high efficacy and specificity. Traditional drug discovery methods can be time-consuming and costly, often resulting in limited success rates.
Solution
Novorex utilizes fragment-based drug design (FBDD) and artificial intelligence to accelerate the discovery of small-molecule drugs, primarily focused on oncology and neurology. Their approach integrates biophysical analysis and in vitro/in vivo assays to optimize drug candidates for enhanced efficacy. By leveraging cutting-edge technology throughout the entire drug development process, Novorex aims to create high-efficiency new drugs that address complex disease mechanisms. This seamless drug discovery process enables the identification of promising compounds with improved therapeutic potential.
Target Audience
Novorex's primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for oncology and neurology.
Features
- Fragment-based drug design (FBDD) for efficient hit identification and lead optimization
- Artificial intelligence algorithms to predict drug-target interactions and optimize compound properties
- Biophysical analysis to characterize drug binding and selectivity
- In vitro and in vivo assays to evaluate drug efficacy and safety